SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is experiencing heightened volatility and intense social media debate as investors weigh a massive post-IPO share unlock against the company's long-term growth prospects. The community is sharply divided between those bracing for a potential sell-off due to the influx of new supply and long-term supporters who view the dip as an opportunity to accumulate shares.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing a significant surge following a strong earnings report that featured record revenue and raised full-year guidance, fueling heavy discussion among the community regarding a potential short squeeze due to high short interest. Investors are actively debating the company's path to profitability and its strategic shift toward becoming a broader enterprise agentic AI platform, with many anticipating increased momentum as the company integrates its recent acquisition and continues to expand its enterprise customer base.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors monitor the company's aggressive business development, including a $2.8 billion deal to acquire AtaiBeckley, aimed at diversifying its neuroscience portfolio beyond its dominance in the GLP-1 weight-loss and diabetes market. The community is actively debating the competitive pressure from Novo Nordisk's oral formulations and the sustainability of Lilly's premium valuation amidst ongoing legal battles over advertising claims.

Nintendo Co., Ltd. engages in the development, manufacture, and sale of home entertainment products. Its entertainment products include portable and console game machines and software, trump cards and Karuta (Japanese-style playing cards), multinational consumer electronics, home console hardware such as Nintendo Wii, Nintendo DS, Nintendo 3DS, as well as software for handheld and home console gaming machines. The company was founded by Fusajiro Yamauchi on September 23, 1889 and is headquartered in Kyoto, Japan.

Nintendo Co. Ltd - ADR

Nintendo is currently facing significant volatility as investors weigh strong hardware demand for the Switch 2 against cooling software sales and mounting input cost pressures from the semiconductor sector. The community remains deeply divided, with some betting on a long-term turnaround driven by the companys powerful intellectual property and entertainment expansion, while others are offloading shares due to concerns over compressed margins and weak forward guidance.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin shares experienced a sharp decline following second-quarter results that missed revenue expectations and provided softer-than-anticipated guidance. While the company continues to demonstrate robust profit margins and remains a focal point for AI-driven advertising, the community is actively debating whether the current sell-off represents a temporary overreaction or a necessary valuation reset given elevated investor expectations.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera is trending as investors rally around the company's platform validation, driven by major partnership deals with pharmaceutical giants Jazz and Vertex that provide non-dilutive capital and long-term royalty potential. The community is focused on the high-stakes Phase 2 clinical readout for ABCL635, viewing it as a critical binary catalyst that could significantly rerate the stock as it transitions from a discovery platform to a proprietary drug developer.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy is experiencing significant volatility and downward pressure as investors weigh concerns over project execution, margin compression, and institutional stake reductions against the company's massive backlog and exposure to the growing AI data center power demand. While some community members view the sharp price decline as a forced shakeout of leveraged positions and a potential long-term buying opportunity, others remain skeptical about the firm's ability to translate secured backlog into profitable earnings without a shift in management or operational strategy.

Investment Managers Series Trust II - Tradr 2X Long SNDK Daily ETF

Tradr 2X Long SNDK Daily ETF

Investors are actively debating the viability of $SNXX as a leveraged play on Sandisk ($SNDK), with sentiment split between those capitalizing on high-volatility momentum and those concerned about the impact of reverse splits and decay. The community is heavily focused on the stock's massive earnings growth and potential AI-driven demand, while simultaneously navigating the risks of extreme price swings inherent in 2x daily ETFs.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors intensely scrutinize upcoming second-quarter earnings for signs of a turnaround, with sentiment heavily divided between those betting on Matrix-M platform licensing deals and those frustrated by a perceived lack of clear communication from management. Community discourse remains dominated by intense debate over the status of its respiratory vaccine collaborations and skepticism regarding current leadership.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is trending as investors aggressively position themselves ahead of the upcoming earnings report, with the community closely tracking potential margin improvements and international growth. While some investors fear further volatility due to heavy short interest and sector competition, many are viewing the current price as a key accumulation opportunity based on the brand's long-term market expansion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LLY Q2 Earnings Top, GLP-1 Drugs Fuel Growth, Sales Guidance Raised

LLY crushes Q2 earnings estimates and lifts its 2026 sales outlook as Mounjaro and Zepbound fuel strong revenue growth and newer drugs add momentum.

Are SOLS, LXP, ATAI Obtaining Fair Deals for their Shareholders?

Are SOLS, LXP, ATAI Obtaining Fair Deals for their Shareholders? Are SOLS, LXP, ATAI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 4, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

Will Mounjaro & Zepbound Drive Lilly's Q2 Results: Buy, Sell or Hold?

LLY is set to report Q2 results on Aug. 5, with GLP-1 drugs expected to drive growth as investors watch Foundayo's early sales.

Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lower 

Equity

Drugmakers have announced 37 biotech acquisitions worth at least $1 billion this year, topping the previous annual record.

How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33%

The consensus price target hints at a 33.3% upside potential for AtaiBeckley Inc (ATAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders?

Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders? Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 21, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk

LLY's leadership in obesity drugs, expanding pipeline and stronger growth outlook set it apart as investors weigh it against NVO in 2026.

Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates

Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates PR Newswire NEW YORK, July 21, 2026 Major Depressive Disorder Market Poised for Strong Growth as New Drug Innovations...

ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside

H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.


ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders

ARKG sold 1.12 million ATAI shares last week but still held 3.19 million shares as of Friday.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.11	--	--	N/A
Q1 '26	-$0.11	-$0.08	26.46%	BEAT
Q4 '25	-$0.11	-$1.73	-1538.26%	MISSED
Q3 '25	-$0.12	-$0.28	-142.59%	MISSED
Q2 '25	-$0.12	-$0.14	-20.00%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings